Daniela A Ferraro
Impact of Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer
Ferraro D, Hermanns T, Kaufmann P, Omlin A, Kranzbühler H, Gablinger R, Müller A, Müller J, Eberli D, Muehlematter U, Garcia Schüler H, Burger I. Impact of Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer. Eur J Nucl Med Mol Imaging 2019
Dec 4, 2019Impact of Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer
Dec 4, 2019Eur J Nucl Med Mol Imaging 2019
Ferraro Daniela A, Hermanns Thomas, Kaufmann Philipp A, Omlin Aurelius, Kranzbühler Helmut, Gablinger Roger, Müller Alexander, Müller Julian, Eberli Daniel, Muehlematter Urs J, Garcia Schüler Helena I, Burger Irene A
First clinico-pathological evidence of a non PSMA-related uptake mechanism for Ga-PSMA-11 in salivary glands
Rupp N, Schibli R, Eberli D, Huber G, Morand G, Messerli M, Ferraro D, Mühlematter U, Müller J, Töpfer A, Lenggenhager D, Pizzuto D, Umbricht C, Burger I. First clinico-pathological evidence of a non PSMA-related uptake mechanism for Ga-PSMA-11 in salivary glands. J Nucl Med 2019
Feb 8, 2019First clinico-pathological evidence of a non PSMA-related uptake mechanism for Ga-PSMA-11 in salivary glands
Feb 8, 2019J Nucl Med 2019
Rupp Niels J, Schibli Roger, Eberli Daniel, Huber Gerhard, Morand Grégoire B, Messerli Michael, Ferraro Daniela A, Mühlematter Urs Jacob, Müller Julian, Töpfer Antonia, Lenggenhager Daniela, Pizzuto Daniele A, Umbricht Christoph A, Burger Irene A
Clinical impact of Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction
Müller J, von Schulthess G, Kaufmann P, Kranzbuehler H, John H, Zilli T, Müller A, Omlin A, Schmid D, Sulser T, Kroeze S, Guckenberger M, Eberli D, Kedzia S, Garcia Schüler H, Muehlematter U, Ferraro D, Burger I. Clinical impact of Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. Eur J Nucl Med Mol Imaging 2018
Nov 28, 2018Clinical impact of Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction
Nov 28, 2018Eur J Nucl Med Mol Imaging 2018
Müller Julian, von Schulthess Gustav K, Kaufmann Philipp A, Kranzbuehler Helmut, John Hubert, Zilli Thomas, Müller Alexander, Omlin Aurelius, Schmid Daniel M, Sulser Tullio, Kroeze Stephanie G C, Guckenberger Matthias, Eberli Daniel, Kedzia Sarah, Garcia Schüler Helena I, Muehlematter Urs J, Ferraro Daniela A, Burger Irene A